An organotropism atlas that predicts where a cancer will spread
Different cancers favour different organs, and so do different patients. A model that predicts which organ is at risk could target surveillance and prevention.
Site of relapse is recorded in registries and trial datasets but almost never modelled as an outcome. Linking primary tumour genomics, transcriptomics and digital pathology to first-relapse site across tens of thousands of patients would produce an organotropism predictor, and would identify the features that drive lung, liver, bone and brain tropism in humans rather than in mice.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- Data silos · Records, scans, genomes and outcomes sit in separate systems that cannot talk. Every patient's experience is lost to the next.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaLink every national cancer registry to tumour genomics
Shares AACR Project GENIE, SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries, Data silos.
- IdeaPool every immunotherapy trial's biomarker data into one commons
Shares cBioPortal for Cancer Genomics, AACR Project GENIE, RNA sequencing & expression profiling, Pathology & radiology foundation models.
- IdeaEmulate the trial in real-world data first to decide which trials to run
Shares AACR Project GENIE, SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries.
- IdeaA global rapid tissue donation network for metastatic disease
Shares cBioPortal for Cancer Genomics, AACR Project GENIE, Metastasis is understood least and studied last, Data silos.
- IdeaAutomatic weekly linkage of cancer registries to deaths, prescriptions and imaging
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries, Data silos.
- IdeaA national late-effects registry linking treatment exposures to outcomes decades later
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries, Data silos.
- IdeaMake a population cancer registry a condition of every cancer aid programme
Shares SEER (Surveillance, Epidemiology, and End Results), Weak real-world evidence and registries, Data silos.
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares cBioPortal for Cancer Genomics, SEER (Surveillance, Epidemiology, and End Results), Data silos.